In addition to being a senior investigator at the CHU de Quebec–Université Laval Research Center and professor in the Faculty of Pharmacy at Laval University, Dr. Di Paolo is also an associate professor at the University of Saskatchewan, Saskatoon, Canada. She received the Janssen-Ortho pharmaceutical research award from the Association of Faculties of Pharmacy of Canada (2002); the Heinz Lehmann prize from the Canadian College of Neuopsychopharmacology, 2003; distinctions: Femmes réussite region Chaudière Appalache, Journal Économique de Québec, 2004, Femme de mérite, YWCA of Québec, Science and technology category, 2006, Empreintes d’elles, YWCA, honoring 400 women, 400th anniversary of Québec City, 2008 and the Diamond prize for excellence in Fundamental Research, Centre Hospitalier Universitaire de Québec, Québec City, 2015.

Dr. Di Paolo has published over 295 peer-reviewed articles and 470 summaries. Her research interest is on Parkinson’s disease and L-Dopa-induced dyskinesias in the post-mortem human brains of Parkinson’s disease patients, non-human primates, and rodent models of Parkinson. This research was and is currently funded by the CIHR, NSERC, Parkinson Society Canada, CQDM, NIH and contracts from Prexton Therapeutics, Novartis, and Merck Serono. 

In recent years, her research has focused on the glutamatergic neurotransmission and the implication of ionotropic and metabotropic glutamate receptors. Various specific antagonists, positive and negative allosteric modulators of glutamate receptors were investigated to inhibit or prevent the development of L-Dopa-induced dyskinesias. Drugs of various pharmacological activities are also investigated in her laboratory including, serotoninergic drugs, omega-3, plasmalogens and dehydroepiandrosterone (DHEA). She recently investigated the effect of a subthalamic lesion on L-Dopa-induced dyskinesias in parkinsonian monkeys, and is now working on the effect of deep stimulation in this area of the brain.

A major research endeavour in her laboratory is also to investigate neuroprotection in a mouse model of Parkinson’s Disease. Repurposing drugs used to treat various endocrine conditions were found to be neuroprotective such as estrogen, progesterone, the selective estrogen receptor modulator raloxifene, and the 5α-reductase inhibitor, dutasteride. Novel non-genomic mechanisms of action were investigated in this neuroprotection, including the implication of the membrane estrogen receptor (GPER1) and the effect of cholesterol on membrane microviscosity.

CHUL
2705, boulevard Laurier
T-2-50
Québec, Québec
Canada G1V 4G2

Latest news

Data not available

271 entries « 1 of 55 »

Morissette M, Morin N, Rouillard C, Di Paolo T

Membrane cholesterol removal and replenishment affect rat and monkey brain monoamine transporters.

Journal Article

Neuropharmacology, 133 , pp. 289-306, 2018, ISSN: 0028-3908.

Abstract | Links:

Mosher LJ, Godar SC, Morissette M, McFarlin KM, Scheggi S, Gambarana C, Fowler SC, Di Paolo T, Bortolato M

Steroid 5α-reductase 2 deficiency leads to reduced dominance-related and impulse-control behaviors.

Journal Article

Psychoneuroendocrinology, 91 , pp. 95-104, 2018, ISSN: 0306-4530.

Abstract | Links:

Bourque M, Morissette M, Di Paolo T

Repurposing sex steroids and related drugs as potential treatment for Parkinson's disease.

Journal Article

Neuropharmacology, 2018, ISSN: 0028-3908.

Abstract | Links:

Morissette M, Di Paolo T

Non-human primate models of PD to test novel therapies.

Journal Article

J Neural Transm, 125 (3), pp. 291-324, 2018, ISSN: 0300-9564.

Abstract | Links:

Bourque M, Gregoire L, Di Paolo T

The plasmalogen precursor analog PPI-1011 reduces the development of L-DOPA-induced dyskinesias in de novo MPTP monkeys.

Journal Article

Behav Brain Res, 337 , pp. 183-185, 2018, ISSN: 0166-4328.

Abstract | Links:

271 entries « 1 of 55 »

Active projects

  • Centre de recherche en endocrinologie, métabolisme et inflammation, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-06-01 to 2023-04-30
  • Centre hospitalier universitaire de Québec - CHU de Québec-Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Centre thématique de recherche en neurosciences, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1999-06-01 to 2020-10-18
  • Institut sur le vieillissement et la participation sociale des aînés, Subvention, Institutionnel - BDR, Instituts reconnus, from 2002-06-01 to 2019-04-30
  • Mechanisms of therapeutic efficacy of deep brain stimulation in Parkinson's disease, Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2015-07-01 to 2020-06-30

Recently finished projects

  • Gonadal drugs for brain neuroprotection and neuromodulation, Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2012-04-01 to 2017-03-31
  • Neuroprotection and immunomodulation in the enteric nervous system for the treatment of Parkinson's disease, Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2012-10-01 to 2018-03-31
Data provided by the Université Laval research projects registery